Alzheimer's Amyloid Hypothesis and Antibody Therapy: Melting Glaciers?

Abstract

The amyloid cascade hypothesis for Alzheimer's disease is still alive, although heavily challenged. Effective anti-amyloid immunotherapy would confirm the hypothesis' claim that the protein amyloid-beta is the cause of the disease. Two antibodies, aducanumab and lecanemab, have been approved by the U.S. Food and Drug Administration, while a third, donanemab, is under review. The main argument for the FDA approvals is a presumed therapy-induced removal of cerebral amyloid deposits. Lecanemab and donanemab are also thought to cause some statistical delay in the determination of cognitive decline. However, clinical efficacy that is less than with conventional treatment, selection of amyloid-positive trial patients with non-specific amyloid-PET imaging, and uncertain therapy-induced removal of cerebral amyloids in clinical trials cast doubt on this anti-Alzheimer's antibody therapy and hence on the amyloid hypothesis, calling for a more thorough investigation of the negative impact of this type of therapy on the brain.

• Authors: Poul F Høilund-Carlsen, Abass Alavi, Rudolph J Castellani, Rachael L Neve, George Perry, Mona-Elisabeth Revheim, Jorge R Barrio
• Journal: International journal of molecular sciences (Int J Mol Sci) Vol. 25 Issue 7 (Mar 31 2024) ISSN: 1422-0067 [Electronic] Switzerland
• PMID: 38612701 (Publication Type: Journal Article, Review)

Chemical References

• donanemab
• Amyloidogenic Proteins
• Antibodies, Monoclonal, Humanized

Topics

• United States
• Humans
• Alzheimer Disease (therapy)
• Ice Cover
• Amyloidogenic Proteins
• Radioimmunotherapy
• Antibodies, Monoclonal, Humanized